E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma

Cancer Research

Volumn 69, Issue 9, 2009, Pages 4052-4058

  Molina Privado, Irene ^a   Rodríguez Martínez, María ^a   Rebollo, Patricia ^a   Martín Pérez, Daniel ^b   Artiga, María Jesús ^b   Menárguez, Javier ^c   Flemington, Erik K ^d   Piris, Miguel A ^b   Campanero, Miguel R ^a,e  

^a CSIC   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURKITT LYMPHOMA; CARCINOGENESIS; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEREGULATION; DIPLOIDY; DOWN REGULATION; E2F1 ONCOGENE; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; SCID MOUSE;

ACTINS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL DIVISION; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER;

EID: 65949095429     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4617     Document Type: Article

References (37)

1. Shapira J. Peylan-Ramu N. Burkitt's lymphoma. Oral Oncol 1998; 34: 15-23.
2. Yustein JT. Dang CV. Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol 2007; 14: 375-81.
3. Patte C. Auperin A. Gerrard M. et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-80.
4. Hecht JL. Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18: 3707-21.
5. Hotchin NA. Allday MJ. Crawford DH. Deregulated c-myc expression in Epstein-Barr-virus-immortalized B-cells induces altered growth properties and surface phenotype but not tumorigenicity. Int J Cancer 1990; 45: 566-71.
6. Johnson DG. Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Front Biosci 1998; 3: 447-58.
7. DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim Biophys Acta 2002; 1602: 131-50.
8. Tsantoulis PK. Gorgoulis VG. Involvement of E2F transcription factor family in cancer. Eur J Cancer 2005; 41: 2403-14.
9. Futterer A. Campanero MR. Leonardo E. et al. Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest 2005; 115: 2351-62.
10. Jaffe ES. Harris NL. Stein H. Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001.
11. Campanero MR. Flemington EK. Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci U S A 1997; 94: 2221-6.
12. Campanero MR. Armstrong M. Flemington E. Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol Cell Biol 1999; 19: 8442-50.
13. Ross DT. Scherf U. Eisen MB. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 227-35.
14. Thorley-Lawson DA. Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 2008; 6: 913-24.
15. Nilsson K. Giovanella BC. Stehlin JS. Klein G. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer 1977; 19: 337-44.
16. Ben-Bassat H. Goldblum N. Mitrani S. et al. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D. G.-75). Int J Cancer 1977; 19: 27-33.
17. Felsher DW. Zetterberg A. Zhu J. Tlsty T. Bishop JM. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A 2000; 97: 10544-8.
18. Packham G. Cleveland JL. c-Myc and apoptosis. Biochim Biophys Acta 1995; 1242: 11-28.
19. 1/S transition and DNA replication. Cancer Cell 2003; 3: 311-6.
20. Seguin L. Liot C. Mzali R. et al. CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP and MKLP1 in S-phase. Mol Cell Biol 2009; 29: 570-81.
21. Campanero MR. Mechanisms involved in Burkitt's tumor formation. Clin Transl Oncol 2008; 10: 250-5.
22. Dave SS. Fu K. Wright GW. et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-42.
23. Hummel M. Bentink S. Berger H. et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-30.
24. Zhang SY. Liu SC. Al-Saleem LF. et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 2000; 9: 395-401.
25. Zacharatos P. Kotsinas A. Evangelou K. et al. Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol 2004; 203: 744-53.
26. Hunt KK. Deng J. Liu TJ. et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 1997; 57: 4722-6.
27. Hao H. Dong Y. Bowling MT. Gomez-Gutierrez JG. Zhou HS. McMasters KM. E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation. BMC Cancer 2007; 7: 24.
28. Bramis J. Zacharatos P. Papaconstantinou I. et al. E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res 2004; 24: 3041-7.
29. Teitell MA. The TCL1 family of oncoproteins: coactivators of transformation. Nat Rev Cancer 2005; 5: 640-8.
30. Ishida S. Huang E. Zuzan H. et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001; 21: 4684-99.
31. Polager S. Kalma Y. Berkovich E. Ginsberg D. E2Fs upregulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene 2002; 21: 437-46.
32. Ren B. Cam H. Takahashi Y. et al. E2F integrates cell cycle progression with DNA repair, replication, and G (2)/M checkpoints. Genes Dev 2002; 16: 245-56.
33. Neufeld TP. de la Cruz AF. Johnston LA. Edgar BA. Coordination of growth and cell division in the Drosophila wing. Cell 1998; 93: 1183-93.
34. 2/M transcription. EMBO J 2004; 23: 4615-26.
35. Field SJ. Tsai FY. Kuo F. et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-61.
36. Yamasaki L. Jacks T. Bronson R. Goillot E. Harlow E. Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-48.
37. DeRyckere D. DeGregori J. E2F1 and E2F2 are differentially required for homeostasis-driven and antigen-induced T cell proliferation in vivo. J Immunol 2005; 175: 647-55.